05:18 AM EDT, 10/17/2024 (MT Newswires) -- Verastem Oncology (VSTM) said Thursday that updated data from a phase 2 study evaluating the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer demonstrated "robust" overall response rates.

The company said all evaluable patients with measurable disease showed a confirmed overall response rate of 31%, with about 12 months of follow-up and a data cutoff of June 30. The median progression-free survival was 12.9 months in all evaluable patients, Verastem ( VSTM ) added.

The company said it is on track to submit the therapy's new drug application for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer to the US Food and Drug Administration in October.

Price: 3.3796, Change: +0.05, Percent Change: +1.49